Case Report: Tislelizumab combined with bevacizumab in the treatment of primary malignant pericardial mesothelioma - Takeaways - MDSpire

Case Report: Tislelizumab combined with bevacizumab in the treatment of primary malignant pericardial mesothelioma

  • By

  • Zijuan Liu

  • Yating Yan

  • Caihong Jiang

  • June 16, 2026

  • 0 min

Share

  • 1

    Primary malignant pericardial mesothelioma (PMPM) is a rare tumor with a prevalence rate of less than 0.002% and poor prognosis.

  • 2

    The patient in the case study experienced significant symptom relief after 29.4 months of treatment with tislelizumab and bevacizumab.

  • 3

    Imaging assessments during treatment indicated stable disease, with no severe adverse reactions leading to mortality reported.

  • 4

    The patient's survival of 2.76 years contrasts with the average survival of 6–10 months reported in previous studies.

  • 5

    The case highlights the potential of tislelizumab and bevacizumab for patients unable to tolerate standard chemotherapy for PMPM.

Original Source(s)

Case Report: Tislelizumab combined with bevacizumab in the treatment of primary malignant pericardial mesothelioma

  • by Zijuan Liu, Yating Yan, Caihong Jiang

  • June 16, 2026

Related Content

Case Report: ETV6 c.744del gene mutation acute lymphoblastic leukemia in identical twins

Oncology Organization and Oncologist Networks Under Medicare Advantage Plans

Circular RNAs as molecular bridges: dual regulation of ferroptosis and immunity in cancer